Inovio Pharmaceuticals INO Institutional Ownership

Updated Oct 11, 2026

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was held by 105 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• These investors held 33.03% of outstanding shares in Q2 2026, down from 38.12% the quarter before.
• Total shares held in INO rose 8.90% from Q1 2026; the number of holders rose 5.00% from Q2 2025.
• Of the 105 holders of INO in Q2 2026, 52 added to their positions, 15 reduced their stakes and 38 left their positions unchanged.
• Institutional investors held 34.16Mn shares of Inovio Pharmaceuticals in total at the end of Q2 2026, up 2.79Mn from the prior quarter and up 24.56Mn from a year earlier.
• As of June 30, 2026, FMR LLC held the largest stake in Inovio Pharmaceuticals with 8.45Mn shares, or 8.18% of shares outstanding.
• The biggest increases in INO positions during Q2 2026 came from Two Sigma Investments, LP (+849.39K shares), Vanguard Capital Management LLC (+749.35K shares), ADAR1 Capital Management, LLC (+673.8K shares), Boxer Capital Management, LLC (+474.87K shares) and HRT Financial LP (+127.52K shares).
• Holders that trimmed the most shares of Inovio Pharmaceuticals in Q2 2026 while keeping a position were FMR LLC (-884.82K shares), D. E. Shaw & Co., Inc. (-861.16K shares), Millennium Management LLC (-614.74K shares), Renaissance Technologies LLC (-282.44K shares) and Northern Trust Corp (-124.48K shares).
• Inovio Pharmaceuticals' 10 largest institutional shareholders as of Q2 2026 were FMR LLC (8.45Mn shares), Jupiter Topco LLC (5.17Mn shares), Vanguard Capital Management LLC (3.65Mn shares), Boxer Capital Management, LLC (2.84Mn shares), ADAR1 Capital Management, LLC (2.14Mn shares), D. E. Shaw & Co., Inc. (1.35Mn shares), Stonepine Capital Management, LLC (1.35Mn shares), Two Sigma Investments, LP (1.24Mn shares), Eversept Partners, LP (1.04Mn shares) and Geode Capital Management, LLC (802.75K shares), per Business Quant data.